Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...

GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC between February 5, 2020 and August 14, 2022. GSK is ...

Moderna's norovirus vaccine trial paused due to a rare neurological effect, Citadel's short position in GSK, bird flu response issues during Trump's term, WHO's call for alcohol warning labels, and ...

(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.